Eric Singhi, Thoracic Medical Oncologist at MD Anderson Cancer Center, shared on X:
“10 WCLC26 abstracts beyond the presidentials to watch
Precision Therapy
1. FURVENT (Abstract #396) – Firmonertinib vs chemotherapy in 1L EGFR exon20ins NSCLC.
Can targeted therapy outperform chemo in the frontline setting?
2. TRIDENT-3 (Abstract #2661) – Repotrectinib vs crizotinib in TKI-naïve ROS1+ NSCLC.
How does the newer-generation ROS1 TKI improve upon our older standard?
ADCs + Novel Combinations
3. IZA-BREN (Abstract #2668) – EGFR×HER3 bispecific ADC in metastatic EGFR-mutated NSCLC.
Where could ADCs fit after EGFR-targeted therapy?
4. BNT324-01 (Abstract #2164) – Pumitamig (PD-L1×VEGF-A bispecific) + Elfe-D (B7-H3 ADC) in NSCLC/SCLC.
Can a bispecific + ADC combination unlock greater activity?
SCLC
5. DeLLphi-309 (Abstract #661) – Extended-interval tarlatamab dosing in ES-SCLC.
Can we dose less frequently while maintaining benefit?
6. DeLLphi-308 (Abstract #773) – Subcutaneous tarlatamab in ES-SCLC.
Can a new route of administration reduce treatment burden for patients?
Local Therapy
7. LONESTAR (#3378) – Local consolidation after nivolumab + ipilimumab in metastatic NSCLC.
Does adding local therapy after dual immunotherapy improve outcomes?
8. BRAIN SRT + OSIMERTINIB (#1889) – Cranial stereotactic radiation in osimertinib-treated NSCLC with limited brain metastases.
With a CNS-active TKI, when does adding brain radiation still matter?
Biomarkers plus Treatment Selection
9. BRAF + IMMUNOTHERAPY (#3125) – Immunotherapy outcomes in NSCLC with class II & III BRAF alterations.
How should we approach immunotherapy in these less well-defined BRAF subtypes?
10. TUMOR BUDDING (#3102) – IASLC tumor budding grade in resected lung squamous cell carcinoma.
Can tumor budding identify higher-risk patients, and predict adjuvant chemotherapy benefit?
You may also find this interesting:
Stage III NSCLC Management 2026: Powerful Advances Transforming Multimodal Care